A 26-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE CONTROLLED, MULTICENTER, MULTINATIONAL SAFETY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS DURING TREATMENT WITH SYMBICORT® , A FIXED COMBINATION OF INHALED CORTICOSTEROID (ICS) (BUDESONIDE) AND A LONG ACTING ß2 - AGONIST (LABA)(FORMOTEROL) AS COMPARED TO TREATMENT WITH ICS (BUDESONIDE) ALONE IN ADULT AND ADOLESCENT (≥12 YEARS OF AGE) PATIENTS WITH ASTHMA. : A 26-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE CONTROLLED, MULTICENTER, MULTINATIONAL SAFETY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS DURING TREATMENT WITH SYMBICORT® , A FIXED COMBINATION OF INHALED CORTICOSTEROID (ICS) (BUDESONIDE) AND A LONG ACTING ß2 - AGONIST (LABA)(FORMOTEROL) AS COMPARED TO TREATMENT WITH ICS (BUDESONIDE) ALONE IN ADULT AND ADOLESCENT (≥ 12 YEARS OF AGE) PATIENTS WITH ASTHMA.
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
WHO International Clinical Trials Registry Platform - (2023) vom: 05. Juni Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 17-02-2012, Last updated: 2023-06-22 |
|---|
| ICTRP ID: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
WHO006009204 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WHO006009204 | ||
| 003 | DE-627 | ||
| 005 | 20230622115356.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210507s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)WHO006009204 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)PER-115-11 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a A 26-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE CONTROLLED, MULTICENTER, MULTINATIONAL SAFETY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS DURING TREATMENT WITH SYMBICORT® , A FIXED COMBINATION OF INHALED CORTICOSTEROID (ICS) (BUDESONIDE) AND A LONG ACTING ß2 - AGONIST (LABA)(FORMOTEROL) AS COMPARED TO TREATMENT WITH ICS (BUDESONIDE) ALONE IN ADULT AND ADOLESCENT (≥12 YEARS OF AGE) PATIENTS WITH ASTHMA. |b A 26-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE CONTROLLED, MULTICENTER, MULTINATIONAL SAFETY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS DURING TREATMENT WITH SYMBICORT® , A FIXED COMBINATION OF INHALED CORTICOSTEROID (ICS) (BUDESONIDE) AND A LONG ACTING ß2 - AGONIST (LABA)(FORMOTEROL) AS COMPARED TO TREATMENT WITH ICS (BUDESONIDE) ALONE IN ADULT AND ADOLESCENT (≥ 12 YEARS OF AGE) PATIENTS WITH ASTHMA. |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 17-02-2012, Last updated: 2023-06-22 | ||
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Phase: Phase 4 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t WHO International Clinical Trials Registry Platform |g (2023) vom: 05. Juni |
| 773 | 1 | 8 | |g year:2023 |g day:05 |g month:06 |
| 856 | 4 | 0 | |u https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=115-11 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 05 |c 06 | ||